Incyte to Report Second Quarter Financial Results

Article Stock Quotes (1)

FREE Breaking News Alerts from StreetInsider.com!

StreetInsider.com Top Tickers, 6/24/2026

1. CBRS
2. FDX
3. KBH
4. HON
5. HTZ

6. MRK
7. TTWO
8. USO
9. QCOM
10. INFY

Get Alerts INCY Hot Sheet

Price: $104.40 --0%

Overall Analyst Rating:
SELL (= Flat)

Revenue Growth %: +29.4%

Join SI Premium – FREE

WILMINGTON, Del.--(BUSINESS WIRE)-- Incyte (Nasdaq: INCY) announced today that it has scheduled its second quarter financial results conference call and webcast for 8:00 a.m. ET on Tuesday, July 30, 2024.

The schedule for the press release and conference call/webcast is as follows:

Q2 2024 Press Release: July 30, 2024 at 7:00 a.m. ET
Q2 2024 Conference Call: July 30, 2024 at 8:00 a.m. ET
Domestic Dial-In Number: 877-407-3042
International Dial-In Number: 201-389-0864
Conference ID Number: 13747471

If you are unable to participate, a replay of the conference call will be available for thirty days. The replay dial-in number for the U.S. is 877-660-6853 and the dial-in number for international callers is 201-612-7415. To access the replay you will need the conference ID number 13747471.

The live webcast with slides can be accessed at Investor.Incyte.com and will be available for replay for ninety days.

About Incyte

A global biopharmaceutical company on a mission to Solve On., Incyte follows the science to find solutions for patients with unmet medical needs. Through the discovery, development and commercialization of proprietary therapeutics, Incyte has established a portfolio of first-in-class medicines for patients and a strong pipeline of products in Oncology and Inflammation & Autoimmunity. Headquartered in Wilmington, Delaware, Incyte has operations in North America, Europe and Asia.

For additional information on Incyte, please visit Incyte.com or follow us on social media: LinkedIn, X, Instagram, Facebook, YouTube.